2/1/2019 6:45:50 AM
Lilly And Loxo Oncology Report Expiration Of HSR Act Waiting Period
1/7/2019 6:32:03 AM
Eli Lilly To Acquire Loxo Oncology For $235/Shr Cash, Or $8.0 Bln
1/7/2019 6:31:34 AM
Eli Lilly To Buy Loxo Oncology For $235/shr In Cash Or About $8.0 Bln
12/21/2018 6:47:35 AM
Loxo Oncology Initiates Phase 1/2 Trial For Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
11/26/2018 7:45:30 PM
Loxo : FDA Oks Vitrakvi, First Ever TRK Inhibitor, For Patients With Advanced Solid Tumors Harboring NTRK Gene Fusion
11/8/2018 6:54:08 AM
Loxo Oncology Q3 Loss Per Share $0.89 Vs Loss $2.45 Last Year
10/15/2018 6:50:46 AM
Loxo Oncology Announces Receipt Of Breakthrough Therapy Designation From FDA For LOXO-292
10/9/2018 6:52:16 AM
Loxo Oncology Announces Details For Data Presentations At The European Society For Medical Oncology 2018 Congress
10/6/2018 9:22:21 AM
Loxo Oncology Announces Updated Interim Clinical Data For LOXO-292 From Global Phase 1/2 LIBRETTO-001 Trial
9/5/2018 6:47:59 AM
Loxo Oncology Announces Receipt Of Breakthrough Therapy Designation From FDA For LOXO-292